You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
In Cell this week: blood immune cell changes in COVID-19 patients and spatial transcriptomics in Alzheimer's disease.
The firms plan to collaborate with others in the field of regenerative medicine and cell therapy to expedite commercialization of the system.
Akadeum's microbubble technology and NanoCellect's Wolf cell-sorting platform will be integrated for high-quality single-cell sequencing of rare cell types.
By running FCS Express on the CyFlow Cube V2m device, Sysmex Parec believes customers will benefit from an analysis software that allows advanced reporting capabilities and data export options.
Cerevance, a drug discovery firm employing the transcriptome sequencing method, raised $45 million in Series B financing earlier this month.
The team characterized immune, viral load, and age differences in children with severe responses to respiratory syncytial virus using an integrated analytical strategy.
The newly launched EndPandemic National Data Consortium brings together seven life sciences and bioinformatics firms in search of treatments and vaccines.
The funding round was led by new investor Co-Win Ventures, with additional investment by existing investors Tramway Partners, Cottonwood Technology Fund, and Sun Mountain Capital.
Oslo-based InstruNor's systems will enable Fluidigm to offer fully automated, walkaway sample preparation for flow and mass cytometry.
In PNAS this week: immune responses that affect heart transplant rejection risk, gene variants associated with thiopurine toxicity, and more.
Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.
Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.
The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.
This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.